We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Larimar Therapeutics Halts Phase 1 Trial of Main Drug Candidate
Larimar Therapeutics Halts Phase 1 Trial of Main Drug Candidate
The FDA has placed Larimar Therapeutics’ phase 1 trial of its experimental Friedrich’s ataxia drug, CTI-1601, on clinical hold, a significant setback for the company as the recombinant fusion protein is the only drug candidate in its pipeline.